Login to Your Account



Other News To Note


Friday, January 13, 2012
• NovAliX SAS, of Strasbourg, France, is partnering with Teijin Pharma Ltd., of Tokyo, to develop drug candidates against multiple targets across different therapeutic areas. Under the collaboration, NovAliX will use its Graffinity SPR-based screening technology to identify novel chemotypes and then engage its nano-MS technology to further characterize selected small-molecule hit structures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription